alendronate has been researched along with Innate Inflammatory Response in 27 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 7.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| "The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks." | 7.88 | Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "Particulated dosage forms of bisphosphonates, such as polymeric nanoparticles and liposomes, deplete circulating monocytes and attenuate inflammation." | 5.34 | Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. ( Golomb, G; Koroukhov, N; Markovsky, E, 2007) |
| "Mechanical loading and alendronate (ALN) can be used as noninvasive physical therapy methods for osteoarthritis (OA)." | 4.31 | Axial Compressive Loading Attenuates Early Osteoarthritis by Reducing Subchondral Bone Remodeling. ( Cai, H; Fu, L; Li, G; Liu, C; Liu, Q; Liu, Y; Pan, Y; Wu, J; Yang, Q; Yu, Y; Zhong, J, 2023) |
| " We report a case of orbital and ocular inflammation secondary to the use of intravenous zoledronic acid and a case of scleritis secondary to oral alendronate." | 4.12 | [Bisphosphonate-induced ocular and orbital inflammation]. ( Funding, M; Jakobsen, TS, 2022) |
| "The proposed therapy using Eplan and alendronate and alphacalcidolum based medicines increases the efficiency of periodontitis therapy, which allows for a faster relief of inflammation of periodontal tissues, bone tissue mineralization, long-term and sustainable disease regression." | 4.02 | [Metabolic bone tissue markers dynamics as criteria for periodontal disease treatment efficiency]. ( Abasnia, SR; Fadeeva, II; Kachesova, ES; Shevchenko, EA; Uspenskaya, OA, 2021) |
| "The anti-catabolic bisphosphonate alendronate is considered as the first-line medical treatment in post-menopausal osteoporosis; but several side effects, including gastric mucosal injury, are associated with its use." | 3.91 | Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats. ( Akkiprik, M; Çilingir-Kaya, ÖT; Ercan, F; Gürler, EB; Peker Eyüboglu, I; Reiter, RJ; Yegen, BÇ, 2019) |
| "The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks." | 3.88 | Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018) |
| " We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis." | 3.81 | Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. ( Cantarini, L; Frediani, B; Iannone, F; Lopalco, G; Rigante, D; Vitale, A, 2015) |
| " Alendronate microparticles were prepared using mucoadhesive polymers such as chitosan for improving the intestinal cellular absorption of alendronate and also using a gastric-resistant polymer such as Eudragit L100-55 for reducing the gastric inflammation of alendronate." | 3.77 | Alendronate-loaded microparticles for improvement of intestinal cellular absorption. ( Baek, JS; Cho, CW; Hwang, JS; Kim, YR; Kwon, HH; Lee, JM; Shin, SC; Sung, HC, 2011) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| " Recent data asserted that cell inflammation could be reversed by the addition of some isoprenoids, such as geranylgeraniol and farnesyl pyrophosphate." | 3.74 | Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. ( De Leo, L; Decorti, G; Marcuzzi, A; Not, T; Pontillo, A; Tommasini, A; Ventura, A, 2008) |
| "Alendronate (ALN) is a nitrogen-containing bisphosphonate (NBP) that inhibits bone resorption." | 1.48 | Alendronate augments lipid A-induced IL-1β release and Smad3/NLRP3/ASC-dependent cell death. ( Kiyoura, Y; Tamai, R, 2018) |
| "Alendronate was administered at 100 μg/kg, orally, once a day." | 1.38 | Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. ( Alcaraz, MJ; Caeiro, JR; Ferrándiz, ML; Guede, D; Ibáñez, L; Maicas, N; Motterlini, R, 2012) |
| "Particulated dosage forms of bisphosphonates, such as polymeric nanoparticles and liposomes, deplete circulating monocytes and attenuate inflammation." | 1.34 | Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. ( Golomb, G; Koroukhov, N; Markovsky, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Rimondi, E | 1 |
| Valencic, E | 1 |
| Tommasini, A | 2 |
| Secchiero, P | 1 |
| Melloni, E | 1 |
| Marcuzzi, A | 4 |
| Kniha, K | 1 |
| Rink, L | 1 |
| Wolf, J | 1 |
| Möhlhenrich, SC | 1 |
| Peters, F | 1 |
| Heitzer, M | 1 |
| Hölzle, F | 1 |
| Modabber, A | 1 |
| Jakobsen, TS | 1 |
| Funding, M | 1 |
| Wu, J | 1 |
| Pan, Y | 1 |
| Yu, Y | 1 |
| Yang, Q | 1 |
| Liu, Q | 1 |
| Liu, Y | 1 |
| Zhong, J | 1 |
| Fu, L | 1 |
| Cai, H | 1 |
| Liu, C | 1 |
| Li, G | 1 |
| Silva, RAB | 1 |
| Sousa-Pereira, AP | 1 |
| Lucisano, MP | 1 |
| Romualdo, PC | 1 |
| Paula-Silva, FWG | 1 |
| Consolaro, A | 1 |
| Silva, LAB | 1 |
| Nelson-Filho, P | 1 |
| Uspenskaya, OA | 1 |
| Kachesova, ES | 1 |
| Abasnia, SR | 1 |
| Shevchenko, EA | 1 |
| Fadeeva, II | 1 |
| Xie, Z | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| Sun, X | 1 |
| Chen, S | 1 |
| Qin, A | 1 |
| Zhu, P | 1 |
| Zhang, J | 1 |
| Fan, S | 1 |
| Tamai, R | 1 |
| Kiyoura, Y | 1 |
| Açil, Y | 1 |
| Arndt, ML | 1 |
| Gülses, A | 1 |
| Wieker, H | 1 |
| Naujokat, H | 1 |
| Ayna, M | 1 |
| Wiltfang, J | 1 |
| Zameer, S | 1 |
| Kaundal, M | 1 |
| Vohora, D | 1 |
| Ali, J | 1 |
| Kalam Najmi, A | 1 |
| Akhtar, M | 1 |
| Gürler, EB | 1 |
| Çilingir-Kaya, ÖT | 1 |
| Peker Eyüboglu, I | 1 |
| Ercan, F | 1 |
| Akkiprik, M | 1 |
| Reiter, RJ | 1 |
| Yegen, BÇ | 1 |
| Lopalco, G | 1 |
| Rigante, D | 1 |
| Vitale, A | 1 |
| Frediani, B | 1 |
| Iannone, F | 1 |
| Cantarini, L | 1 |
| Yao, W | 1 |
| Lay, YE | 1 |
| Kot, A | 1 |
| Liu, R | 1 |
| Zhang, H | 1 |
| Chen, H | 1 |
| Lam, K | 1 |
| Lane, NE | 1 |
| Hoefert, S | 1 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 1 |
| Pontillo, A | 3 |
| Paoluzzi, E | 1 |
| Crovella, S | 3 |
| Baek, JS | 1 |
| Kwon, HH | 1 |
| Hwang, JS | 1 |
| Sung, HC | 1 |
| Lee, JM | 1 |
| Shin, SC | 1 |
| Kim, YR | 1 |
| Cho, CW | 1 |
| Piscianz, E | 2 |
| Girardelli, M | 1 |
| Ibáñez, L | 1 |
| Alcaraz, MJ | 1 |
| Maicas, N | 1 |
| Guede, D | 1 |
| Caeiro, JR | 1 |
| Motterlini, R | 1 |
| Ferrándiz, ML | 1 |
| Zanin, V | 1 |
| Vuch, J | 1 |
| Bianco, AM | 1 |
| Monasta, L | 1 |
| Decorti, G | 2 |
| Funayama, H | 3 |
| Ohsako, M | 1 |
| Monma, Y | 1 |
| Mayanagi, H | 1 |
| Sugawara, S | 3 |
| Endo, Y | 4 |
| Yu, Z | 2 |
| Deng, X | 2 |
| Kuroishi, T | 1 |
| Sasano, T | 2 |
| Yamaguchi, K | 2 |
| Markovsky, E | 1 |
| Koroukhov, N | 1 |
| Golomb, G | 1 |
| Pitocco, D | 1 |
| Collina, MC | 1 |
| Musella, T | 1 |
| Ruotolo, V | 1 |
| Caputo, S | 1 |
| Manto, A | 1 |
| Caradonna, P | 1 |
| Galli, M | 1 |
| Mancini, L | 1 |
| Ghirlanda, G | 1 |
| Bodde, EW | 1 |
| Kowalski, RS | 1 |
| Spauwen, PH | 1 |
| Jansen, JA | 1 |
| De Leo, L | 1 |
| Not, T | 1 |
| Ventura, A | 1 |
| Motegi, K | 1 |
| Iwakura, Y | 1 |
1 review available for alendronate and Innate Inflammatory Response
| Article | Year |
|---|---|
Interaction between IGF-1, inflammation, and neuropathy in the pathogenesis of acute charcot neuroarthropathy: lessons from alendronate therapy and future perspectives of medical therapy.
Topics: Acute Disease; Alendronate; Arthropathy, Neurogenic; Bone Density Conservation Agents; Bone Resorpti | 2008 |
26 other studies available for alendronate and Innate Inflammatory Response
| Article | Year |
|---|---|
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Autophagy; Biosynthetic Pathways; Cell De | 2021 |
Host inflammatory response and clinical parameters around implants in a rat model using systemic alendronate and zoledronate acid drug administrations.
Topics: Alendronate; Animals; Dental Implants; Inflammation; Interleukin-6; Metal Nanoparticles; Osseointegr | 2022 |
[Bisphosphonate-induced ocular and orbital inflammation].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Inflammation; Scleritis | 2022 |
Axial Compressive Loading Attenuates Early Osteoarthritis by Reducing Subchondral Bone Remodeling.
Topics: Alendronate; Animals; Bone Remodeling; Cartilage, Articular; Disease Models, Animal; Inflammation; M | 2023 |
Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Female; Humans; | 2020 |
[Metabolic bone tissue markers dynamics as criteria for periodontal disease treatment efficiency].
Topics: Alendronate; Alkaline Phosphatase; Bone and Bones; Chronic Periodontitis; Humans; Inflammation | 2021 |
Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.
Topics: Alendronate; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Bone Resorptio | 2018 |
Alendronate augments lipid A-induced IL-1β release and Smad3/NLRP3/ASC-dependent cell death.
Topics: Alendronate; Amino Acid Chloromethyl Ketones; Animals; CARD Signaling Adaptor Proteins; Caspase 1; C | 2018 |
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokin | 2018 |
Ameliorative effect of alendronate against intracerebroventricular streptozotocin induced alteration in neurobehavioral, neuroinflammation and biochemical parameters with emphasis on Aβ and BACE-1.
Topics: Alendronate; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid End | 2019 |
Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats.
Topics: Alendronate; Animals; Bone Matrix; Female; Gastritis; Inflammation; Melatonin; Osteoporosis; Ovariec | 2019 |
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
Topics: Adult; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combina | 2015 |
Improved Mobilization of Exogenous Mesenchymal Stem Cells to Bone for Fracture Healing and Sex Difference.
Topics: Adipose Tissue; Alendronate; Animals; Bone Density; Bony Callus; Dipeptides; Female; Femoral Fractur | 2016 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency.
Topics: Alendronate; Carrier Proteins; Child; Female; Humans; Inflammation; Leukocytes, Mononuclear; Lipopol | 2010 |
Alendronate-loaded microparticles for improvement of intestinal cellular absorption.
Topics: Acrylic Resins; Alendronate; Biological Availability; Bone Density Conservation Agents; Caco-2 Cells | 2011 |
Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes.
Topics: Alendronate; Animals; Apoptosis; Biomarkers; Biosynthetic Pathways; Caspase 1; Caspase 3; Caspase In | 2011 |
Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Arthritis; Biomarkers; Disease Models, Animal; Down- | 2012 |
The effect of clodronate on a mevalonate kinase deficiency cellular model.
Topics: Adolescent; Adult; Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Cells, Cult | 2012 |
Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antimetabolites; Bone and Bones; Bone Resorption; Cl | 2005 |
Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Aspirin; Bone Density Conservation Agents; Clodronic | 2005 |
Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Clodronic Acid; Female; Histidine Decarboxyl | 2007 |
Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition.
Topics: Albumins; Alendronate; Animals; Carotid Stenosis; Cell Line; Cross-Linking Reagents; Diffusion; Drug | 2007 |
No increased bone formation around alendronate or omeprazole loaded bioactive bone cements in a femoral defect.
Topics: Alendronate; Animals; Bone Cements; Bone Density; Bone Density Conservation Agents; Enzyme Inhibitor | 2008 |
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Acyclic Monoterpenes; Alendronate; Animals; Disease Models, Anima | 2008 |
Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.
Topics: Alendronate; Animals; Diphosphonates; Drug Interactions; Escherichia coli; Histidine Decarboxylase; | 2000 |